Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
25 sept. 2023 07h00 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
20 sept. 2023 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve...
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
11 sept. 2023 07h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of James Robinson to its Board of Directors effective...
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
06 sept. 2023 07h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the publication of a study evaluating tegoprubart as an immunomodulatory...
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
05 sept. 2023 07h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the first participant has been dosed in the Company’s Phase 2 BESTOW trial...
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
16 août 2023 07h00 HE
|
Eledon Pharmaceuticals, Inc.
10th patient dosed marks achievement of first clinical milestone associated with next tranche of funding Eledon to report updated interim clinical data from the ongoing Phase 1b trial of tegoprubart...
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
10 août 2023 07h00 HE
|
Eledon Pharmaceuticals, Inc.
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation; updated clinical data expected in the fourth quarter Raised up to $185 million,...
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
06 juil. 2023 04h00 HE
|
AKAMPION
Ongoing Phase IIb study expands to arm B5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantationSecond closing of Series A...
Medical Biomimetics Industry Research 2023
19 juin 2023 09h18 HE
|
Research and Markets
Dublin, June 19, 2023 (GLOBE NEWSWIRE) -- The "Medical Biomimetics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" report has been added to ...
Organ Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market Research
07 juin 2023 13h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, June 07, 2023 (GLOBE NEWSWIRE) -- The global organ transplant rejection medication market is estimated to flourish at a CAGR of 3.9% from 2023 to 2031. According...